Barriers and facilitators to buprenorphine use for opioid agonist treatment: protocol for a scoping review.

ABSTRACT:

Introduction

In the context of the opioid crisis in North America, the benefits of evidence-based opioid agonist treatments such as buprenorphine/naloxone have not been optimised due to low uptake. Numerous factors contribute to the underuse of buprenorphine, and theory-informed approaches to identify and address implementation barriers and facilitators are needed. This scoping review aims to characterise the barriers and facilitators at the patient, healthcare professional, organisation and system level according to the Theoretical Domains Framework (TDF), and identify gaps to inform practice and policy.

Methods and analysis

We will conduct a scoping review using established methods and follow the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension

SUBMITTER: Leece P 

PROVIDER: S-EPMC6924699 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature